Considering the deleterious effects of overproduction of endogenous NO in sepsis, several NOS inhibitors, including selective and nonselective, have been developed, and the therapeutic efficacy and safety of these compounds have been widely investigated. This evidence concerns the gene NOS2 and Sepsis.